Overview
Henry Ogbuagu is a Hospital Medicine specialist and a Physiatrist in Belleville, Illinois. Dr. Ogbuagu is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Dysarthria, and Myringotomy.
His clinical research consists of co-authoring 6 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
4500 Memorial Dr, Belleville, IL 62226
4700 Waters Ave, Savannah, GA 31404
405 W Jackson St, Carbondale, IL 62901
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- DysarthriaDr. Ogbuagu isExperienced. Learn about Dysarthria.
- MyringotomyDr. Ogbuagu isExperienced. Learn about Myringotomy.
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)